Datopotamab Deruxtecan Demonstrates Meaningful Survival Benefit in First-Line Metastatic TNBC
Recent findings from the phase 3 TROPION-Breast02 trial, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, are reshaping the treatment landscape for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). Data revealed that datopotamab deruxtecan (Dato-DXd) considerably improved both overall survival (OS) and progression-free survival (PFS) compared to standard-of-care chemotherapy in patients for whom immunotherapy isn’t a viable option.
At a median follow-up of 27.5 months, Dato-DXd demonstrated a statistically significant enhancement of over 5 months in both median OS and PFS. Specifically, the trial showed an OS hazard ratio (HR) of 0.79 (95% CI, 0.64-0.98; *P* = .0291) and a PFS HR of 0.57 (95% CI, 0.47-0.69). These results represent a ample step forward for patients facing this aggressive disease.
Comparing Dato-DXd to Other Antibody-Drug Conjugates (ADCs) in TNBC
The emergence of multiple adcs in TNBC treatment necessitates a careful consideration of their individual characteristics and optimal sequencing. Sacituzumab govitecan, already established in clinical practice, offers a valuable option but is often associated with myelosuppression, diarrhea, and fatigue.
A key differentiator for Dato-DXd, and a critical factor for many oncologists, is its potential for central nervous system (CNS) penetration. This is particularly important for patients with brain metastases or those at high risk of developing them. Sacituzumab tirumotecan is another ADC showing promise, but its efficacy and safety profile require further evaluation in larger, more diverse populations – particularly outside of Asian cohorts were initial data originates.
Ultimately, a crucial question remains: which ADC will demonstrate the most synergistic effect when combined with immune checkpoint inhibitors, potentially minimizing side effects while maximizing efficacy? Furthermore, exploring the role of these ADCs in the early breast cancer setting, aiming for curative potential through CNS activity, is a vital area of ongoing research.
Post-Progression Strategies and Second-Line Options
The TROPION-Breast02 trial also highlighted the importance of stabilizing disease with a first-line therapy, allowing patients to remain fit enough to receive subsequent lines of treatment.Many patients in the trial went on to receive further novel therapies, including other ADCs and emerging agents like bispecific antibodies that modulate the tumor microenvironment.
While detailed analysis is ongoing, preliminary data suggests that initial stabilization with Dato-DXd may enhance the effectiveness of these subsequent therapies by altering the tumor microenvironment. A deeper dive into the post-progression treatment patterns will provide valuable insights into optimal sequencing strategies.
Reference:
Dent R, Shao Z, Schmid P, et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: primary results from the randomised, phase III TROPION-Breast02 trial. Presented at: 50th European Society for Medical Oncology Congress; October 17-21, 2025; Berlin, Germany. abstract LBA21.
Worth a look